Association of diabetic macular edema and proliferative diabetic retinopathy with cardiovascular disease a systematic review and meta-analysis

JAMA Ophthalmology

Volumn 135, Issue 6, 2017, Pages 586-593

  Xie, Jing ^a   Ikram, M Kamran ^b   Cotch, Mary Frances ^b,c   Klein, Barbara ^d   Varma, Rohit ^e   Shaw, Jonathan E ^f   Klein, Ronald ^d   Mitchell, Paul ^g   Lamoureux, Ecosse L ^b   Wong, Tien Yin ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL EYE INSTITUTE   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF ILLINOIS   (United States)

^f BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; REVIEW; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETIC RETINOPATHY; GLOBAL HEALTH; MACULAR EDEMA; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETIC RETINOPATHY; GLOBAL HEALTH; HUMANS; INCIDENCE; MACULAR EDEMA; RISK FACTORS;

EID: 85020707284     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2017.0988     Document Type: Review

References (38)

1. Yau JW, Rogers SL, Kawasaki R, et al.; Meta-analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35(3): 556-564.
2. Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 1992; 15(12):1875-1891.
3. Cheung N, Wong TY. Diabetic retinopathy and systemic vascular complications. Prog Retin Eye Res. 2008; 27(2):161-176.
4. Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2007; 30(7): 1742-1746.
5. Klein R, Klein BE, Moss SE, Cruickshanks KJ. Association of ocular disease and mortality in a diabetic population. Arch Ophthalmol. 1999; 117(11): 1487-1495.
6. Lip GY, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: the loire valley atrial fibrillation project. Chest. 2015; 147(4):1103-1110.
7. Hägg S, Thorn LM, Putaala J, et al.; FinnDiane Study Group. Incidence of stroke according to presence of diabetic nephropathy and severe diabetic retinopathy in patients with type 1 diabetes. Diabetes Care. 2013; 36(12):4140-4146.
8. Kramer CK, Rodrigues TC, Canani LH, Gross JL, Azevedo MJ. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. Diabetes Care. 2011; 34(5):1238-1244.
9. Liew G, Mitchell P. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2007; 356(7):747-748.
10. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2009; 20(3):158-165.
11. Crowther MJ, Riley RD, Staessen JA, Wang J, Gueyffier F, Lambert PC. Individual patient data meta-analysis of survival data using Poisson regression models. BMC Med Res Methodol. 2012; 12:34.
12. Mitchell P, Smith W, Wang JJ, Attebo K. Prevalence of diabetic retinopathy in an older community: the Blue Mountains Eye Study. Ophthalmology. 1998; 105(3):406-411.
13. Carnethon MR, Biggs ML, Barzilay J, et al. Diabetes and coronary heart disease as risk factors for mortality in older adults. Am J Med. 2010; 123(6): 556.e1-556.e9. doi:10.1016/j.amjmed.2009.11.023
14. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989; 129(4):687-702.
15. Dunstan DW, Zimmet PZ, Welborn TA, et al.; Australian Diabetes, Obesity and Lifestyle Study (AusDiab). The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)-methods and response rates. Diabetes Res Clin Pract. 2002; 57(2):119-129.
16. Klein R, Klein BEK, Linton KLP, De Mets DL. The Beaver Dam Eye Study: visual acuity. Ophthalmology. 1991; 98(8):1310-1315.
17. Attebo K, Mitchell P, Smith W. Visual acuity and the causes of visual loss in Australia: the Blue Mountains Eye Study. Ophthalmology. 1996; 103(3): 357-364.
18. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991; 1(3):263-276.
19. Varma R, Paz SH, Azen SP, et al.; Los Angeles Latino Eye Study Group. The Los Angeles Latino Eye Study: design, methods, and baseline data. Ophthalmology. 2004; 111(6):1121-1131.
20. Bild DE, Detrano R, Peterson D, et al. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2005; 111(10):1313-1320.
21. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol. 1994; 112(9):1217-1228.
22. Ong YT, De Silva DA, Cheung CY, et al. Microvascular structure and network in the retina of patients with ischemic stroke. Stroke. 2013; 44(8):2121-2127.
23. Karnik AA, Fields AV, Shannon RP. Diabetic cardiomyopathy. Curr Hypertens Rep. 2007; 9(6): 467-473.
24. Brooks BA, Franjic B, Ban CR, et al. Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. Diabetes Obes Metab. 2008; 10(9):739-746.
25. Akasaka T, Yoshida K, Hozumi T, et al. Retinopathy identifies marked restriction of coronary flow reserve in patients with diabetes mellitus. J Am Coll Cardiol. 1997; 30(4):935-941.
26. Miura H, Wachtel RE, Loberiza FR Jr, et al. Diabetes mellitus impairs vasodilation to hypoxia in human coronary arterioles: reduced activity of ATP-sensitive potassium channels. Circ Res. 2003; 92(2):151-158.
27. Faglia E, Favales F, Calia P, et al.; Milan Study on Atherosclerosis and Diabetes (Mi SAD). Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease: 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes (MiSAD). Diabetes Care. 2002; 25(11): 2032-2036.
28. Yoon JK, Lee KH, Park JM, et al. Usefulness of diabetic retinopathy as a marker of risk for thallium myocardial perfusion defects in non-insulin-dependent diabetes mellitus. Am J Cardiol. 2001; 87(4):456-459, A6.
29. Sari I, Soydinc S, Davutoglu V, Sezen Y, Aksoy M. Uncomplicated diabetes mellitus is equivalent for coronary artery disease: new support from novel angiographic myocardial perfusion-myocardial blush. Int J Cardiol. 2008; 127(2):262-265.
30. Yamagishi S, Matsui T, Ueda S, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes. Cardiovasc Hematol Agents Med Chem. 2007; 5(3):236-240.
31. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res. 2006; 3(1):73-77.
32. Farhangkhoee H, Khan ZA, Kaur H, Xin X, Chen S, Chakrabarti S. Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets. Pharmacol Ther. 2006; 111(2):384-399.
33. Cooper ME. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am J Hypertens. 2004; 17(12, pt 2):31S-38S.
34. Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol. 2001; 1(3):181-193.
35. Williams JG, Rincon-Skinner T, Sun D, et al. Role of nitric oxide in the coupling of myocardial oxygen consumption and coronary vascular dynamics during pregnancy in the dog. Am J Physiol Heart Circ Physiol. 2007; 293(4):H2479-H2486.
36. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996; 19(3):257-267.
37. Dafer RM, Schneck M, Friberg TR, Jay WM. Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol. 2007; 22(3):201-204.
38. Martin DF, Maguire MG, Fine SL, et al.; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012; 119(7):1388-1398.